C. Difficile

A study on vancomycin treatment, new data on the investigational Pfizer C diff vaccine, how individual antibiotics are ranked by risk for C difficile infection, and more.

The Phase 3 CLOVER trial still showed safety and potential benefits by reducing C difficile infection duration, medical attention needs, and antibiotic use.

Teena Chopra, MD, MPH, FACP, FIDSA, FSHEA, and Matthew D. Sims, MD, PhD, FACP, FIDSA, provide clinical insights on the rate of recurrence of C. difficile infections and the impact on patients.

A panel of experts provide an overview of the epidemiology of Clostridioides difficile infections, highlighting diagnostic practices and the role of antimicrobial stewardship.

The study found that vancomycin is more effective than metronidazole in achieving event-free survival for C difficile infections across all infection severity levels.

Jeffery Silber MD, highlights VE303's consistent formulation as an advantage over traditional fecal transplants and discusses how the trial's patient-centric approach aims to improve outcomes and reduce healthcare-associated infections.

Individual antibiotics are ranked by risk for C difficile infection in an analysis of both randomized controlled trials and national adverse event reports.

Enhanced diagnostic and surveillance measures for hypervirulent pathogens, new CDC safety data on RSV vaccines showing rare risks, updated IDSA guidance for managing antimicrobial-resistant infections, and more this week from Contagion.

Here is a review of the most up-to-date information around the infection.

A bill in the House of Representatives was just introduced with the advocacy of the Peggy Lillis Foundation in hopes of bringing more recognition and research to the healthcare-associated infection.

A hospital CDI intervention program that supported patients via an ID specialist demonstrated clinical benefits compared to another hospital where patients were followed by providers of any specialty.

A secondary analysis of a randomized trial points to limited benefits on the microbiota.

This week, NYC has revealed high rates of Hepatitis C virus reinfection, SHEA tackles antimicrobial resistance amidst challenges during the COVID-19 pandemic, and more this week from Contagion.

This week, the resurgence of leptospirosis in Wyoming, insights on COVID-19 reinfection severity, avian influenza cases in the US, challenges in medical communication amid scientific advancements, recent FDA recalls, and more from Contagion.

Mutations in YabG affect spore germination and substrate processing, offering insights into its essential functions in the lifecycle of C diff.

DDW 2024 highlighted advances in managing recurrent C difficile infections, emphasis on the effectiveness of live biotherapeutic products and the impact of antibiotic stewardship, and more ongoing efforts in combating C difficile.

The FDA recalls ice cream, orzo, and mixed nuts. Also this week, interviews with Jared Baeten, MD, PhD, on Lenacapavir's 100% efficacy against HIV, and Jason Roberts, PhD, on the promise of continuous β-Lactam against sepsis, and more from Contagion.

A Florida hospital takes a novel approach for the healthcare-associated infection and reduced inappropriate testing by setting up guidelines.

A case study of an 80-year-old patient, illustrating successful management of dual H pylori and C diff infections with quadruple therapy, with key insights from Yazan Abboud, MD and Sima Vossough-Teehan, MD.

Researchers assess the efficacy of fecal microbiota transplantation (FMT) for first or second episodes of Cdifficile infection (CDI), demonstrating high initial cure rates and sustained in managing the condition.

In a small study, recurrent Clostridioides difficile infection (CDI) therapy, Rebyota, was durable in a majority of patients who were exposed to non-CDI antibiotics.

FDA approves pneumococcal vaccine V116, Salmonella outbreak linked to a household pet, Japan is currently facing an unprecedented surge in cases of streptococcal toxic shock syndrome, and more this week from Contagion.

In a 17-year study across 2 Québec hospitals, researchers explored the relationship between antibiotic use and healthcare-associated Clostridioides difficile infections.

Presented at DDW 2024 by Ken Blount, the effectiveness of live biotherapeutic products in treating recurrent C difficile infections (rCDI), offering insights into microbiota alteration and prospects for management.

The link between vancomycin susceptibility and decreasing sustained clinical response in C difficile infections.

Vedanta Biosciences initiates the Phase 3 RESTORATiVE303 clinical trial, marking a pivotal moment in the battle against this recurrent infection.

This week, a strategic approach along with existing treatments aimed at reducing incidence rates and curing people of HCV, advocating Lyme disease research in honor of May being its awareness month, Digestive Disease Week coverage, and more this week from Contagion.

Antimicrobial stewardship to reduce multidrug resistance and opportunistic Clostridioides difficile infection (CDI) could also guide shorter treatment.

This week, new WHO data illustrates challenges during the acute phase of the COVID-19 pandemic, MAD-ID and ACVR conference coverage, and more from Contagion.

In patients with Clostridium difficile infection (CDI), ibezapolstat was shown to have similar results to a standard of care therapy.